{"id":"eszopiclone-lunesta","safety":{"commonSideEffects":[{"rate":"15-21%","effect":"Headache"},{"rate":"10-15%","effect":"Dizziness"},{"rate":"10-14%","effect":"Somnolence"},{"rate":"5-34%","effect":"Unpleasant taste"},{"rate":"5-10%","effect":"Anxiety"},{"rate":"5-7%","effect":"Dry mouth"},{"rate":"1-3%","effect":"Hallucinations"},{"rate":"<1%","effect":"Complex sleep behaviors"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eszopiclone is the active S-enantiomer of zopiclone and acts as a positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) in the central nervous system. This potentiation of GABAergic neurotransmission results in sedative, hypnotic, anxiolytic, and muscle relaxant effects. The drug preferentially binds to GABA-A receptors containing alpha-1 subunits, which are associated with sleep promotion.","oneSentence":"Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to promote sleep onset and maintenance.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:45.645Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Insomnia (sleep onset and sleep maintenance)"}]},"trialDetails":[{"nctId":"NCT03668041","phase":"PHASE3","title":"National Adaptive Trial for PTSD Related Insomnia","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-02-25","conditions":"Insomnia","enrollment":673},{"nctId":"NCT07332442","phase":"PHASE3","title":"Continuous Positive Airway Pressure, Arousability and Links to Mechanisms in Obstructive Sleep Apnea","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-02","conditions":"Sleep Apnea, Obstructive Sleep Apnea","enrollment":250},{"nctId":"NCT05951023","phase":"PHASE2","title":"Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2023-08-31","conditions":"Obstructive Sleep Apnea","enrollment":42},{"nctId":"NCT03937713","phase":"PHASE4","title":"Effectiveness of Combining Behavioral and Pharmacologic Therapy for Complex Insomnia in Veterans With PTSD","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2019-12-01","conditions":"Complex Insomnia","enrollment":53},{"nctId":"NCT05953610","phase":"PHASE2","title":"Endotypic Traits and Obstructive Sleep Apnea Surgery","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2024-01-07","conditions":"Obstructive Sleep Apnea","enrollment":150},{"nctId":"NCT07018557","phase":"PHASE4","title":"Impact of Eszopiclone on Blood Pressure in Patients With Insomnia and Hypertension (PRYSMA-HTN)","status":"RECRUITING","sponsor":"University of Sao Paulo","startDate":"2025-06-04","conditions":"Insomnia, Hypertension","enrollment":150},{"nctId":"NCT04980703","phase":"NA","title":"Grain Moxibustion Treatment on Insomnia: a Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Institute of Acupuncture, Moxibustion and Meridian","startDate":"2027-07-01","conditions":"Sleep Initiation and Maintenance Disorders","enrollment":102},{"nctId":"NCT06640023","phase":"NA","title":"The Study in Outpatient Medicine Using Nudges to Improve Sleep","status":"ENROLLING_BY_INVITATION","sponsor":"University of Southern California","startDate":"2024-12-20","conditions":"Inappropriate Prescribing","enrollment":443},{"nctId":"NCT06928766","phase":"PHASE2","title":"Effects of Eszopiclone and Lemborexant in People With OSA With a Low Arousal Threshold Who Have Difficulty Sleeping","status":"NOT_YET_RECRUITING","sponsor":"Flinders University","startDate":"2025-05-01","conditions":"OSA - Obstructive Sleep Apnea","enrollment":15},{"nctId":"NCT04875364","phase":"PHASE2","title":"Do Endotypes Predict Response and Sequelae in OSA Patients","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2020-08-01","conditions":"Obstructive Sleep Apnea, Sleep Apnea, Sleep Apnea, Obstructive","enrollment":200},{"nctId":"NCT06452953","phase":"NA","title":"Modified Suanzaoren Decoction Versus Eszopiclone for the Treatment of Chronic Insomnia Disorder","status":"COMPLETED","sponsor":"Central South University","startDate":"2020-09-10","conditions":"Chronic Insomnia Disorder","enrollment":85},{"nctId":"NCT05293600","phase":"PHASE1, PHASE2","title":"Rescue Pharmacotherapy for OSA","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-07-01","conditions":"Obstructive Sleep Apnea","enrollment":70},{"nctId":"NCT04639193","phase":"PHASE2","title":"Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-12-01","conditions":"OSA, Obstructive Sleep Apnea","enrollment":20},{"nctId":"NCT02456532","phase":"PHASE4","title":"Safety and Efficacy of Chronic Hypnotic Use 2","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2015-08-05","conditions":"Chronic Insomnia","enrollment":41},{"nctId":"NCT06017921","phase":"PHASE4","title":"Effect of Eszopiclone on Adherence to CPAP and Severity of Insomnia in Patients With COMISA","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-08-24","conditions":"Obstructive Sleep Apnea, Insomnia","enrollment":60},{"nctId":"NCT00812214","phase":"PHASE4","title":"Treatment of Insomnia in Migraineurs","status":"COMPLETED","sponsor":"MedVadis Research Corporation","startDate":"2007-04","conditions":"Insomnia, Migraine","enrollment":113},{"nctId":"NCT01605253","phase":"PHASE4","title":"Eszopiclone for the Treatment of Posttraumatic Stress Disorder","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2012-03","conditions":"Posttraumatic Stress Disorders","enrollment":81},{"nctId":"NCT00511134","phase":"PHASE4","title":"Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban","status":"TERMINATED","sponsor":"Yale University","startDate":"2007-04","conditions":"Insomnia, Nicotine Dependence","enrollment":4},{"nctId":"NCT05349396","phase":"PHASE1","title":"Bioavailability of Eszopiclone 3.0 mg With Regards to Reference Product","status":"COMPLETED","sponsor":"Laboratorios Andromaco S.A.","startDate":"2022-04-11","conditions":"Bioequivalence","enrollment":28},{"nctId":"NCT00392041","phase":"PHASE4","title":"Eszopiclone in the Treatment of Insomnia and Fibromyalgia","status":"COMPLETED","sponsor":"Lesley A. Allen, Ph.D.","startDate":"2006-08","conditions":"Fibromyalgia, Insomnia","enrollment":36},{"nctId":"NCT02087488","phase":"NA","title":"Auricular Acupuncture for Primary Insomnia","status":"COMPLETED","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2014-03","conditions":"Primary Insomnia","enrollment":288},{"nctId":"NCT01887691","phase":"PHASE1","title":"Sleep Effectiveness and Insulin and Glucose Homeostasis","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2012-10","conditions":"Diabetes, Prediabetic, Prediabetes","enrollment":20},{"nctId":"NCT00374556","phase":"NA","title":"Insomnia and Osteoarthritis Study","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2006-01","conditions":"Osteoarthritis, Insomnia","enrollment":30},{"nctId":"NCT02455271","phase":"","title":"Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2012-10-01","conditions":"Insomnia","enrollment":438},{"nctId":"NCT02452684","phase":"","title":"Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2012-10-01","conditions":"Insomnia","enrollment":4876},{"nctId":"NCT00247624","phase":"PHASE4","title":"Improving Sleep and Psychological Functioning in People With Depression and Insomnia","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2005-10","conditions":"Sleep Initiation and Maintenance Disorders, Depression","enrollment":60},{"nctId":"NCT00857220","phase":"PHASE3","title":"Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-05","conditions":"Insomnia, Attention Deficit Hyperactivity Disorder","enrollment":304},{"nctId":"NCT00889200","phase":"PHASE4","title":"Eszopiclone Treatment & Cortisol Responsivity","status":"COMPLETED","sponsor":"Butler Hospital","startDate":"2007-05","conditions":"Insomnia","enrollment":12},{"nctId":"NCT00900159","phase":"NA","title":"Effects of Daytime Eszopiclone Administration in Shift Workers","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2009-05","conditions":"Shift-Work Sleep Disorder","enrollment":24},{"nctId":"NCT01641900","phase":"NA","title":"Effects of Eszopiclone on Sleep and Memory in Schizophrenia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-07","conditions":"Schizophrenia","enrollment":59},{"nctId":"NCT01102270","phase":"EARLY_PHASE1","title":"The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2009-01","conditions":"Obstructive Sleep Apnea","enrollment":17},{"nctId":"NCT01633827","phase":"NA","title":"Combination Therapy to Treat Sleep Apnea","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2012-08","conditions":"Sleep Apnea, Obstructive","enrollment":22},{"nctId":"NCT00822679","phase":"PHASE4","title":"Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2007-10","conditions":"Acute Coronary Syndrome, Sleep Disorder","enrollment":5},{"nctId":"NCT00365261","phase":"PHASE4","title":"Effect of Eszopiclone on Sleep Disturbance and Pain in Cancer","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2006-09","conditions":"Sleep Initiation and Maintenance Disorders","enrollment":45},{"nctId":"NCT00120250","phase":"PHASE4","title":"Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2005-06","conditions":"Post-Traumatic Stress Disorders","enrollment":27},{"nctId":"NCT00616655","phase":"PHASE2","title":"Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-01","conditions":"Generalized Anxiety Disorder","enrollment":456},{"nctId":"NCT00386334","phase":"PHASE4","title":"A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2006-10","conditions":"Insomnia","enrollment":388},{"nctId":"NCT00781482","phase":"PHASE4","title":"Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem","status":"WITHDRAWN","sponsor":"Kettering Health Network","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT00414037","phase":"PHASE4","title":"How do Sleeping Pills Affect Pain in the Brain?","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2006-12","conditions":"Primary Insomnia","enrollment":40},{"nctId":"NCT00724282","phase":"PHASE4","title":"Treatment of Insomnia and Glucose Metabolism","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2008-04","conditions":"Sleep, Insomnia, Insulin Resistance","enrollment":20},{"nctId":"NCT01100164","phase":"PHASE3","title":"A Non-inferiority Study With Two Treatment Arms Eszopiclone 3 mg Versus Zopiclone 7.5 mg - for the Treatment of Insomnia","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2011-03","conditions":"INSOMNIA","enrollment":263},{"nctId":"NCT00365976","phase":"PHASE4","title":"Study of the Insomnia in Patients With Low Back Pain","status":"COMPLETED","sponsor":"Duke University","startDate":"2006-08","conditions":"Primary Insomnia","enrollment":58},{"nctId":"NCT00645944","phase":"NA","title":"Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia","status":"COMPLETED","sponsor":"Yale University","startDate":"2008-04","conditions":"Insomnia, Schizophrenia, Schizoaffective Disorder","enrollment":39},{"nctId":"NCT02322658","phase":"PHASE1","title":"Bioequivalence Study of Eszopiclone Tablets, 3 mg Under Fed Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2008-09","conditions":"Healthy","enrollment":46},{"nctId":"NCT02322645","phase":"PHASE1","title":"Bioequivalence Study of Eszopiclone Tablets, 3 mg Under Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2008-08","conditions":"Healthy","enrollment":46},{"nctId":"NCT00833547","phase":"NA","title":"Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2006-09","conditions":"Schizophrenia","enrollment":25},{"nctId":"NCT00460993","phase":"PHASE4","title":"Efficacy & Safety of Eszopiclone (Lunesta) in Nursing Home Patients","status":"COMPLETED","sponsor":"Emory University","startDate":"2005-06","conditions":"Poor Quality Sleep","enrollment":71},{"nctId":"NCT00555750","phase":"NA","title":"Sleep Loss and Mechanisms of Impaired Glucose Metabolism","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2006-03","conditions":"Primary Insomnia","enrollment":20},{"nctId":"NCT00893269","phase":"PHASE1","title":"The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2008-10","conditions":"Marijuana Dependence","enrollment":36},{"nctId":"NCT00856973","phase":"PHASE3","title":"Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-05","conditions":"Insomnia, Attention Deficit Hyperactivity Disorder","enrollment":486},{"nctId":"NCT00324896","phase":"PHASE3","title":"Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2006-05","conditions":"Parkinson's Disease, Insomnia","enrollment":30},{"nctId":"NCT00811746","phase":"NA","title":"Hypnotics to Improve Polysomnography Yield: Eszopiclone vs Ramelteon?","status":"COMPLETED","sponsor":"Southern California Institute for Research and Education","startDate":"2008-12","conditions":"Obstructive Sleep Apnea","enrollment":90},{"nctId":"NCT00515177","phase":"PHASE2, PHASE3","title":"Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2007-08","conditions":"Chronic Insomnia, Primary Insomnia","enrollment":30},{"nctId":"NCT01055834","phase":"PHASE1","title":"A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2010-01","conditions":"Insomnia","enrollment":42},{"nctId":"NCT00770510","phase":"PHASE2, PHASE3","title":"A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2008-09","conditions":"Primary Insomnia","enrollment":192},{"nctId":"NCT00770692","phase":"PHASE3","title":"A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2008-10","conditions":"Insomnia","enrollment":369},{"nctId":"NCT01710631","phase":"PHASE3","title":"Twelve Month Study of the Safety of Eszopiclone in Adult Subjects With Insomnia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2001-02","conditions":"Primary Insomnia","enrollment":791},{"nctId":"NCT00813735","phase":"PHASE4","title":"Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Lehigh Center for Clinical Research","startDate":"2006-09","conditions":"Insomnia","enrollment":60},{"nctId":"NCT00826111","phase":"PHASE4","title":"The Effects of Eszopiclone and Lexapro on Prefrontal Glutamate and GABA in Depression With Anxiety and Insomnia","status":"COMPLETED","sponsor":"Steward St. Elizabeth's Medical Center of Boston, Inc.","startDate":"2007-08","conditions":"Depression, Anxiety, Insomnia","enrollment":19},{"nctId":"NCT00699608","phase":"PHASE3","title":"An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Healthy Subjects, Sleep Initiation and Maintenance Disorders","enrollment":91},{"nctId":"NCT00366093","phase":"PHASE3","title":"Study of Eszopiclone Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause/Menopause","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2004-02","conditions":"Insomnia","enrollment":410},{"nctId":"NCT00235508","phase":"PHASE4","title":"Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2005-06","conditions":"Insomnia, Generalized Anxiety Disorder","enrollment":420},{"nctId":"NCT00368056","phase":"PHASE3","title":"Effects of One Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2005-04","conditions":"Primary Insomnia","enrollment":32},{"nctId":"NCT00435279","phase":"PHASE3","title":"A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2007-06","conditions":"Major Depressive Disorder, Insomnia","enrollment":678},{"nctId":"NCT00352144","phase":"PHASE3","title":"6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-10","conditions":"Primary Insomnia","enrollment":830},{"nctId":"NCT00685269","phase":"PHASE2","title":"Safety and Efficacy of Eszopiclone With Mild to Moderate Obstructive Sleep Apnea Syndrome (OSAS)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-08","conditions":"Obstructive Sleep Apnea Syndrome","enrollment":20},{"nctId":"NCT00368030","phase":"PHASE3","title":"A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2004-01","conditions":"Insomnia, Depressive Disorder, Major","enrollment":545},{"nctId":"NCT00367965","phase":"PHASE3","title":"Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2004-02","conditions":"Insomnia, Arthritis, Rheumatoid","enrollment":153},{"nctId":"NCT00368160","phase":"PHASE1","title":"Study of an Evening Dose of Eszopiclone on Next Day Driving Ability & Psychomotor/Memory Function in Healthy Volunteers","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2004-03","conditions":"Insomnia","enrollment":32},{"nctId":"NCT00628914","phase":"PHASE4","title":"Brain Mechanisms and Targeting Insomnia in Major Depression","status":"UNKNOWN","sponsor":"University of California, Los Angeles","startDate":"2008-05","conditions":"Major Depressive Disorder, Insomnia","enrollment":60},{"nctId":"NCT00374192","phase":"NA","title":"The Treatment of Insomnia in Symptomatic Peri- and Postmenopausal Women","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2006-02","conditions":"Menopause, Insomnia","enrollment":67},{"nctId":"NCT00612157","phase":"PHASE4","title":"Continuous Positive Airway Pressure (CPAP) Promotion And Prognosis - the Army Sleep Apnea Program (ASAP)","status":"COMPLETED","sponsor":"Walter Reed Army Medical Center","startDate":"2008-01","conditions":"Obstructive Sleep Apnea","enrollment":154},{"nctId":"NCT00594087","phase":"NA","title":"Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2006-12","conditions":"Relapsing Remitting Multiple Sclerosis, Sleep Initiation and Maintenance Disorders, Fatigue","enrollment":30},{"nctId":"NCT00283790","phase":"PHASE4","title":"Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-01","conditions":"Insomnia","enrollment":36},{"nctId":"NCT00167375","phase":"","title":"Testing the Nocturnal Sleep Latency Profile in Primary Insomnia","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2005-01","conditions":"Primary Insomnia, Sleep Initiation and Maintenance Disorders","enrollment":24},{"nctId":"NCT00507117","phase":"PHASE4","title":"Ezopiclone Improves the Quality of Overnight Polysomnography","status":"COMPLETED","sponsor":"Walter Reed Army Medical Center","startDate":"2007-03","conditions":"Obstructive Sleep Apnea","enrollment":300}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CHEST DISCOMFORT"},{"count":1,"reaction":"DYSPHAGIA"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"ERYTHEMA"},{"count":1,"reaction":"ERYTHEMA MULTIFORME"},{"count":1,"reaction":"FLUSHING"},{"count":1,"reaction":"HERPES ZOSTER"},{"count":1,"reaction":"HYPERHIDROSIS"},{"count":1,"reaction":"HYPERSENSITIVITY"},{"count":1,"reaction":"MENINGITIS VIRAL"}],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lunesta"],"phase":"marketed","status":"active","brandName":"Eszopiclone (Lunesta)","genericName":"Eszopiclone (Lunesta)","companyName":"Sumitomo Pharma America, Inc.","companyId":"sumitomo-pharma-america-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to promote sleep onset and maintenance. Used for Insomnia (sleep onset and sleep maintenance).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}